Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$108.70 USD

108.70
9,520,162

-1.05 (-0.96%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Swarup Gupta headshot

Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma

The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.

Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod

Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.

Are You Looking for a Top Momentum Pick? Why Merck (MRK) is a Great Choice

Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Stock Market News For Jun 20, 2019

Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.

AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod

AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.

Merck's Keytruda Gets 2nd Label Expansion Approval in June

Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

Merck (MRK) closed at $84.45 in the latest trading session, marking a +1.38% move from the prior day.

Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients

Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.

AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use

AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.

Bayer to Invest 5 Billion Euros in Weedkiller Research

Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.

J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study

J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.

Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz

Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.

Agilent Announces Receipt of FDA Approval for pharmDX Assay

Agilent (A) receives approval on the expanded use of its PD-L1 IHC 22C3 pharmDx assay.

Zachary Stutler headshot

3 Big Pharma Stocks to Buy Right Now

These big pharma stocks all have a Zacks Rank #2 or better.

Swarup Gupta headshot

Dow 30 Stock Roundup: United Technologies-Raytheon Merger, Merck's Tilos Buyout

The index traversed a volatile week, guided largely by trade-related developments.

Kinjel Shah headshot

Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230

Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.

Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock

Here are five reasons why investors may consider betting on Merck (MRK) stock

Novartis Reports Data on Cosentyx for Psoriatic Arthritis

Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.

Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer

Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.

Kinjel Shah headshot

Boost Your Portfolio's Health With These 3 Big Drug Stocks

The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.

Lilly Announces Tradjenta Cardiovascular Outcome Study Data

Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.

Merck (MRK) to Buy Private Biotech Tilos for Up to $773M

Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million

Merck (MRK) Gains But Lags Market: What You Should Know

In the latest trading session, Merck (MRK) closed at $82.48, marking a +0.02% move from the previous day.